Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Signs and Symptoms 1Psoriasis 1Nutrition Disorders 1Insulin Resistance 1Inflammatory Bowel Diseases 1Glioma 1Glioblastoma 1Gastroparesis 1Feeding and Eating Disorders 1Esophageal Neoplasms 1Dumping Syndrome 1Diarrhea 1Breast Neoplasms 1Brain Neoplasms 1Arthritis, Rheumatoid 1

Interventions

Trastuzumab 350Paclitaxel 334Cyclophosphamide 315Docetaxel 291Capecitabine 181Doxorubicin 180Letrozole 165Tamoxifen 145Bevacizumab 124Fulvestrant 118Carboplatin 118exemestane 111Lapatinib 111Anastrozole 111Radiotherapy 105Epirubicin 104Gemcitabine 97palbociclib 83Exercise 78Vinorelbine 77Fluorouracil 77Surveys and Questionnaires 71pertuzumab 67Filgrastim 64Albumin-Bound Paclitaxel 64eribulin 55Magnetic Resonance Spectroscopy 55Everolimus 52Blood Specimen Collection 51Zoledronic Acid 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms × Sulfasalazine × Clear all
NCT03847311 2025-01-09

Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients

University of Arizona

Phase 2 Completed
7 enrolled 8 charts
Breast

Breast Neoplasms, Signs and Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡